{"id":8012,"date":"2023-12-05T12:44:15","date_gmt":"2023-12-05T12:44:15","guid":{"rendered":"https:\/\/dailyai.com\/?p=8012"},"modified":"2023-12-05T12:48:06","modified_gmt":"2023-12-05T12:48:06","slug":"astrazeneca-bets-247m-on-ai-company-developing-cancer-drug","status":"publish","type":"post","link":"https:\/\/dailyai.com\/nb\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","title":{"rendered":"AstraZeneca satser $247 millioner p\u00e5 AI-selskap som utvikler kreftmedisin"},"content":{"rendered":"<p><strong>AstraZeneca har bevilget $247 millioner til \u00e5 finansiere AI-legemiddelutviklingsselskapet Abscis arbeid med \u00e5 utvikle et antistoff mot kreft.<\/strong><\/p>\n<p>Absci bruker sin generative <a href=\"https:\/\/dailyai.com\/nb\/2023\/07\/ai-accelerates-discovery-of-anti-aging-drugs-in-new-study\/\">AI-oppdagelse av legemidler<\/a> plattform for \u00e5 oppdage potensielle nye legemidler, og validerer deretter disse i v\u00e5tlaboratoriene.<\/p>\n<p>Med det AstraZeneca-st\u00f8ttede prosjektet vil Absci fors\u00f8ke \u00e5 lage et antistoff som binder seg til et spesifikt onkologisk m\u00e5l. Selskapet har enn\u00e5 ikke avsl\u00f8rt hvilken type kreft det retter seg mot med dette prosjektet.<\/p>\n<p>Antistoffer er et attraktivt potensial for <a href=\"https:\/\/dailyai.com\/nb\/2023\/06\/researchers-build-breakthrough-ai-model-for-drug-discovery\/\">nye legemidler<\/a> fordi de er sv\u00e6rt selektive n\u00e5r det gjelder hvilke m\u00e5l de binder seg til, og fordi de gir minimale immunogene effekter. Det er imidlertid vanskelig \u00e5 finne et nytt antistoff med spesifikke egenskaper som er lett \u00e5 produsere.<\/p>\n<p>Antallet mulige proteinkombinasjoner for \u00e5 lage ulike antistoffer er praktisk talt ubegrenset. S\u00e5 for \u00e5 finne et antistoff som gj\u00f8r det du vil at det skal gj\u00f8re, m\u00e5 du gjette og pr\u00f8ve deg frem.<\/p>\n<p>Dette gj\u00f8r tradisjonell antistoffoppdagelse sv\u00e6rt tids- og ressurskrevende. Det inneb\u00e6rer screening av store immune eller syntetiske biblioteker for \u00e5 finne potensielle antistoffkandidater. Disse kandidatene m\u00e5 deretter syntetiseres f\u00f8r man kan bekrefte om de vil binde seg optimalt til m\u00e5lmolekylet.<\/p>\n<p>Abscis Integrated Drug Creation-plattform bruker maskinl\u00e6ringsmodeller som er trent opp p\u00e5 v\u00e5tlaboratorieanalyser, eller eksperimentelle prosedyrer, og genererer milliarder av protein-protein-interaksjonsdata.<\/p>\n<p>AI-modellen l\u00e6rer seg de underliggende tekniske prinsippene som gj\u00f8r at ulike proteiner oppf\u00f8rer seg som de gj\u00f8r. Plattformen bruker sin generative AI-motor til \u00e5 skape syntetiske antistoffer de novo, eller fra bunnen av, i en null-shot-tiln\u00e6rming.<\/p>\n<p>For antistoffer betyr en null-shot-tiln\u00e6rming at kandidatproteinene som AI-en genererer, er basert p\u00e5 f\u00f8rste prinsipper, i stedet for \u00e5 basere seg p\u00e5 historiske data om andre proteiner som er kjent for \u00e5 binde seg til et spesifikt patogen.<\/p>\n<p>Ved hjelp av kunstig intelligens kan man mye raskere og mer n\u00f8yaktig \"gjette\" hvilke proteiner som potensielt kan v\u00e6re verdt \u00e5 unders\u00f8ke, enn ved en menneskelig \"hit-and-miss\"-tiln\u00e6rming.<\/p>\n<p>Deretter valideres kandidatproteinene eksperimentelt i Abscis v\u00e5tlaboratorier. AI-plattformen for proteindesign fremskynder oppdagelsen av legemidler ved \u00e5 fullf\u00f8re syklusen med datainnsamling, AI-drevet design og v\u00e5tlaboratorievalidering i l\u00f8pet av omtrent seks uker.<\/p>\n<p>Administrerende direkt\u00f8r Sean McClain i Absci sier om samarbeidet med AstraZeneca: \"AstraZeneca er ledende i utviklingen av nye behandlinger innen onkologi, og vi er glade for \u00e5 samarbeide med dem om \u00e5 utvikle en terapeutisk antistoffkandidat som har potensial til \u00e5 forbedre livet til kreftpasienter.\"<\/p>\n<p>AstraZenecas \u00f8konomiske engasjement i prosjektet er et lovende tegn p\u00e5 at selskapet ser optimistisk p\u00e5 mulighetene for \u00e5 lykkes. Bruk av kunstig intelligens for \u00e5 fremskynde utviklingen av <a href=\"https:\/\/dailyai.com\/nb\/2023\/08\/ai-powered-blood-test-detects-cancers-in-single-dna-molecules\/\">kreft<\/a> legemidler vil ha stor innvirkning p\u00e5 pasientenes liv, s\u00e5 vel som p\u00e5 Big Pharmas \u00f8konomi.<\/p>","protected":false},"excerpt":{"rendered":"<p>AstraZeneca har bevilget $247 millioner kroner til \u00e5 finansiere AI-legemiddelutviklingsselskapet Abscis arbeid med \u00e5 utvikle et antistoff mot kreft. Absci bruker sin generative AI-plattform for legemiddeloppdagelse til \u00e5 oppdage potensielle nye legemidler, og validerer deretter disse i sine v\u00e5tlaboratorier. Med det AstraZeneca-st\u00f8ttede prosjektet vil Absci fors\u00f8ke \u00e5 skape et antistoff som binder seg til et spesifikt onkologisk m\u00e5l. Selskapet har enn\u00e5 ikke avsl\u00f8rt hvilken type kreft de retter seg mot med dette prosjektet. Antistoffer er et attraktivt potensial for nye legemidler fordi de er sv\u00e6rt selektive n\u00e5r det gjelder hvilke m\u00e5l de binder seg til, og fordi de gir minimale immunogene effekter. Det er imidlertid vanskelig \u00e5 finne en<\/p>","protected":false},"author":6,"featured_media":8014,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84],"tags":[150,203,107],"class_list":["post-8012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-ai-benefits","tag-biotech","tag-generative-ai"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca bets $247m on AI company developing cancer drug | DailyAI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dailyai.com\/nb\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:locale\" content=\"nb_NO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dailyai.com\/nb\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"DailyAI\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T12:44:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-05T12:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Eugene van der Watt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:site\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:label1\" content=\"Skrevet av\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eugene van der Watt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ansl. lesetid\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"author\":{\"name\":\"Eugene van der Watt\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\"},\"headline\":\"AstraZeneca bets $247m on AI company developing cancer drug\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"keywords\":[\"AI benefits\",\"Biotech\",\"Generative AI\"],\"articleSection\":[\"Industry\"],\"inLanguage\":\"nb-NO\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\"},\"inLanguage\":\"nb-NO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"width\":1000,\"height\":501},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dailyai.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"name\":\"DailyAI\",\"description\":\"Your Daily Dose of AI News\",\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dailyai.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nb-NO\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\",\"name\":\"DailyAI\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"width\":4501,\"height\":934,\"caption\":\"DailyAI\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DailyAIOfficial\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dailyaiofficial\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@DailyAIOfficial\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\",\"name\":\"Eugene van der Watt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"caption\":\"Eugene van der Watt\"},\"description\":\"Eugene comes from an electronic engineering background and loves all things tech. When he takes a break from consuming AI news you'll find him at the snooker table.\",\"sameAs\":[\"www.linkedin.com\\\/in\\\/eugene-van-der-watt-16828119\"],\"url\":\"https:\\\/\\\/dailyai.com\\\/nb\\\/author\\\/eugene\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca satser $247 millioner p\u00e5 AI-selskap som utvikler kreftmedisin | DailyAI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dailyai.com\/nb\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_locale":"nb_NO","og_type":"article","og_title":"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI","og_description":"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an","og_url":"https:\/\/dailyai.com\/nb\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_site_name":"DailyAI","article_published_time":"2023-12-05T12:44:15+00:00","article_modified_time":"2023-12-05T12:48:06+00:00","og_image":[{"width":1000,"height":501,"url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","type":"image\/jpeg"}],"author":"Eugene van der Watt","twitter_card":"summary_large_image","twitter_creator":"@DailyAIOfficial","twitter_site":"@DailyAIOfficial","twitter_misc":{"Skrevet av":"Eugene van der Watt","Ansl. lesetid":"2 minutter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#article","isPartOf":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"author":{"name":"Eugene van der Watt","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa"},"headline":"AstraZeneca bets $247m on AI company developing cancer drug","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"wordCount":434,"publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","keywords":["AI benefits","Biotech","Generative AI"],"articleSection":["Industry"],"inLanguage":"nb-NO"},{"@type":"WebPage","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","url":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","name":"AstraZeneca satser $247 millioner p\u00e5 AI-selskap som utvikler kreftmedisin | DailyAI","isPartOf":{"@id":"https:\/\/dailyai.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","breadcrumb":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb"},"inLanguage":"nb-NO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"]}]},{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","width":1000,"height":501},{"@type":"BreadcrumbList","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dailyai.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca bets $247m on AI company developing cancer drug"}]},{"@type":"WebSite","@id":"https:\/\/dailyai.com\/#website","url":"https:\/\/dailyai.com\/","name":"DagligAI","description":"Din daglige dose med AI-nyheter","publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dailyai.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nb-NO"},{"@type":"Organization","@id":"https:\/\/dailyai.com\/#organization","name":"DagligAI","url":"https:\/\/dailyai.com\/","logo":{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","width":4501,"height":934,"caption":"DailyAI"},"image":{"@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DailyAIOfficial","https:\/\/www.linkedin.com\/company\/dailyaiofficial\/","https:\/\/www.youtube.com\/@DailyAIOfficial"]},{"@type":"Person","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa","name":"Eugene van der Watt","image":{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","caption":"Eugene van der Watt"},"description":"Eugene har bakgrunn som elektroingeni\u00f8r og elsker alt som har med teknologi \u00e5 gj\u00f8re. N\u00e5r han tar en pause fra AI-nyhetene, finner du ham ved snookerbordet.","sameAs":["www.linkedin.com\/in\/eugene-van-der-watt-16828119"],"url":"https:\/\/dailyai.com\/nb\/author\/eugene\/"}]}},"_links":{"self":[{"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/posts\/8012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/comments?post=8012"}],"version-history":[{"count":5,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/posts\/8012\/revisions"}],"predecessor-version":[{"id":8018,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/posts\/8012\/revisions\/8018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/media\/8014"}],"wp:attachment":[{"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/media?parent=8012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/categories?post=8012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyai.com\/nb\/wp-json\/wp\/v2\/tags?post=8012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}